Sulphonamides vs tetracycline
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
69 questions · 69 findings · 24 reviews
No studies found 22 · 31.9%GRADE not reported 5 · 7.2%Very low 28 · 40.6%Low 9 · 13%Moderate 4 · 5.8%High 1 · 1.4%
Fluoroquinolones vs beta‐lactams
Serious adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
- RR 10.9 [0.61, 194.82]1 study · 221 participantsVery low
Azithromycin vs placebo or usual care
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
- no estimate extracted2 studies · 454 participantsVery low
Azithromycin vs placebo or usual care
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
- RR 1.11 [0.89, 1.4]4 studies · 794 participantsModerate
Oral + inhaled dual therapy vs oral monotherapy
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
- OR 0.48 [0.08, 2.87]1 study · 53 participantsVery low
Macrolide+tetracycline vs macrolides
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyOR 1 [0.52, 1.93]1 study · 198 participantsVery low
Quinolone vs macrolides
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Macrolides vs tetracycline
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Quinolone vs tetracycline
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found